Antithrombotic drugs, which include antiplatelet and anticoagulant therapies, prevent and
treat many cardiovascular disorders and, as such, are some of the most commonly …

Background—Evidence regarding the use of direct oral anticoagulants (DOACs) in the
elderly, particularly bleeding risks, is unclear despite the presence of greater comorbidities …

Atrial fibrillation (AF) confers a substantial risk of mortality and morbidity from stroke and
thrombo-embolism, and this common cardiac arrhythmia represents a major healthcare …

Arterial and venous thromboembolism are leading causes of morbidity and mortality around
the world. For almost 70 years, heparins (unfractionated heparin and low molecular weight …

In patients with non-valvular atrial fibrillation, oral anticoagulation with vitamin K antagonists
reduces the risk of stroke by more than 60%. But vitamin K antagonists have limitations …

Abstract Background Direct oral anticoagulants (DOACs) are used for treatment of venous
thromboembolism (VTE) and stroke prevention in atrial fibrillation (AF). Given the shorter half …

Objectives Dabigatran is a direct thrombin inhibitor shown to be an effective alternative to
warfarin in patients with non-valvular atrial fibrillation (AF). We evaluated the use of …

Edoxaban is a once-daily oral anticoagulant that rapidly and selectively inhibits factor Xa in
a concentration-dependent manner. This review describes the extensive clinical …

Abstract Background and Objectives Atrial fibrillation (AF) and the associated risk of stroke
are emerging epidemics throughout the world. Suboptimal use of oral anticoagulants for …

Introduction: Gastrointestinal bleeding (GIB) is a major problem in patients on oral
anticoagulation therapy. This issue has become even more pressing since the introduction …